PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1346095-9 1992 These results suggest that LACI serves as a cofactor for heparin and thus greatly enhances the inhibition of TF-induced coagulation. Heparin 57-64 coagulation factor III, tissue factor Homo sapiens 109-111 8219221-6 1993 Induction of TF activity by PC-Al was antagonized by dextran sulfate, heparin, fucoidan, and concanavalin A but not by ovalbumin, polyglutamic acid, or polyvinyl sulfate. Heparin 70-77 coagulation factor III, tissue factor Homo sapiens 13-15 1346095-14 1992 Based on the above results, it is concluded that LACI is a cofactor for heparin in the inhibition of TF-induced clotting and that LACI and sulfated polysaccharides act synergistically in whole plasma. Heparin 72-79 coagulation factor III, tissue factor Homo sapiens 101-103 3422166-8 1988 Antithrombin III alpha alone had no effect, but antithrombin III alpha with heparin abrogated the TF inhibition. Heparin 76-83 coagulation factor III, tissue factor Homo sapiens 98-100 1705837-5 1991 Cells growth with HBGF-1/heparin had both decreased surface and total TF activity as compared with HUVEC from the same endothelial cell pool grown without HBGF-1/heparin. Heparin 25-32 coagulation factor III, tissue factor Homo sapiens 70-72 2749591-0 1989 The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Heparin 111-118 coagulation factor III, tissue factor Homo sapiens 31-44 3192507-1 1988 An endothelial cell glycoprotein that inhibits the initiation of the coagulation process promoted by tissue factor has been isolated by heparin-sepharose, hydroxyapatite and gel filtration chromatography. Heparin 136-143 coagulation factor III, tissue factor Homo sapiens 101-114 1964669-4 1990 The interaction of heparin with monocytes reversibly decreases the expression of tissue factor on the cellular surface, so hampering the cellular procoagulant potential. Heparin 19-26 coagulation factor III, tissue factor Homo sapiens 81-94 31903737-10 2020 In vitro coadministration of heparin normalized the procoagulant effect and required dose escalation based on TF expression. Heparin 29-36 coagulation factor III, tissue factor Homo sapiens 110-112 6733045-0 1984 The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor. Heparin 48-55 coagulation factor III, tissue factor Homo sapiens 95-108 31903737-14 2020 The TF procoagulant effect is reversible with heparin. Heparin 46-53 coagulation factor III, tissue factor Homo sapiens 4-6 30412630-9 2018 Low baseline EV-TF predicted a worse survival in the low molecular weight heparin as compared with the control group (HR 1.42; 95% CI 1.04-1.95; P = 0.03; P for interaction = 0.12). Heparin 74-81 coagulation factor III, tissue factor Homo sapiens 16-18 29066620-8 2017 Finally, these AutoAbs enhance tumor growth in mice bearing human prostate cancer xenografts, and heparin derivatives specifically abrogate this effect by blocking AutoAb binding to cell-surface GRP78 and decreasing TF expression/activity. Heparin 98-105 coagulation factor III, tissue factor Homo sapiens 216-218 27852920-4 2017 The purpose of this study was to assess the effect of heparin, including nonanticoagulant (desulfated) heparins, on basal and Thr-induced expression of TF and inflammatory cytokines in DCs. Heparin 54-61 coagulation factor III, tissue factor Homo sapiens 152-154 27852920-4 2017 The purpose of this study was to assess the effect of heparin, including nonanticoagulant (desulfated) heparins, on basal and Thr-induced expression of TF and inflammatory cytokines in DCs. Heparin 103-111 coagulation factor III, tissue factor Homo sapiens 152-154 24266905-0 2014 Early heparin administration attenuates tissue factor-mediated thrombin generation during simulated cardiopulmonary bypass. Heparin 6-13 coagulation factor III, tissue factor Homo sapiens 40-53 27566697-3 2016 Aims of the present study are (1) to evaluate a possible role of low-molecular-weight-heparins (LMWHs) in the modulation of the expression of TF, TFPI, TFPI2 and VEGF in placentae from thrombophilic women and (2) to study the possible role of endothelium in the placental expression of markers involved in haemostasis and angiogenesis. Heparin 86-94 coagulation factor III, tissue factor Homo sapiens 142-144 27405066-9 2016 Finally, TF activity was increased on monocytes exposed to plasma from septic patients, an effect that was attenuated in plasma from patients receiving unfractionated heparin (UFH). Heparin 167-174 coagulation factor III, tissue factor Homo sapiens 9-11 27405066-9 2016 Finally, TF activity was increased on monocytes exposed to plasma from septic patients, an effect that was attenuated in plasma from patients receiving unfractionated heparin (UFH). Heparin 176-179 coagulation factor III, tissue factor Homo sapiens 9-11 27258428-10 2016 Polysialic acid and heparin reversed the histone-induced TF up-regulation and TM down-regulation. Heparin 20-27 coagulation factor III, tissue factor Homo sapiens 57-59 25969127-11 2015 Procoagulant TF activity of therapeutic MSCs is associated with reductions in myocardial perfusion when delivered IC may be successfully managed by heparin coadministration. Heparin 148-155 coagulation factor III, tissue factor Homo sapiens 13-15 24266905-1 2014 BACKGROUND: We tested the hypothesis that heparin administration prior to the emergence of tissue factor (TF) would increase plasma TF pathway inhibitor (TFPI) and attenuate TF-mediated thrombin generation during simulated cardiopulmonary bypass (CPB). Heparin 42-49 coagulation factor III, tissue factor Homo sapiens 106-108 24266905-1 2014 BACKGROUND: We tested the hypothesis that heparin administration prior to the emergence of tissue factor (TF) would increase plasma TF pathway inhibitor (TFPI) and attenuate TF-mediated thrombin generation during simulated cardiopulmonary bypass (CPB). Heparin 42-49 coagulation factor III, tissue factor Homo sapiens 132-134 24266905-10 2014 CONCLUSIONS: Heparin-induced TFPI elevation attenuates TF-mediated thrombin generation. Heparin 13-20 coagulation factor III, tissue factor Homo sapiens 29-31 21946214-0 2011 Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-kappaB. Heparin 21-28 coagulation factor III, tissue factor Homo sapiens 43-56 21946214-2 2011 In this study, the influence of low molecular weight heparin (LMWH) on tissue factor (TF) expression and activity in five cell lines from various tissues was analysed and explored. Heparin 53-60 coagulation factor III, tissue factor Homo sapiens 71-84 21946214-2 2011 In this study, the influence of low molecular weight heparin (LMWH) on tissue factor (TF) expression and activity in five cell lines from various tissues was analysed and explored. Heparin 53-60 coagulation factor III, tissue factor Homo sapiens 86-88 21159364-4 2011 It is the aim of this study to investigate i) the effect of immunomodulatory treatment on endothelial cell tissue factor (TF) expression and function, ii) the regulation of the observed TF activity, and iii) the modulating effect of low molecular weight heparin and aspirin on TF activity in vitro. Heparin 254-261 coagulation factor III, tissue factor Homo sapiens 186-188 22977511-0 2011 Low molecular weight heparin suppresses tissue factor-mediated cancer cell invasion and migration in vitro. Heparin 21-28 coagulation factor III, tissue factor Homo sapiens 40-53 21159364-4 2011 It is the aim of this study to investigate i) the effect of immunomodulatory treatment on endothelial cell tissue factor (TF) expression and function, ii) the regulation of the observed TF activity, and iii) the modulating effect of low molecular weight heparin and aspirin on TF activity in vitro. Heparin 254-261 coagulation factor III, tissue factor Homo sapiens 186-188 20431847-1 2010 Antithrombin (AT), in the presence of heparin, is able to inhibit the catalytic activity of factor VIIa bound to tissue factor (TF) on cell surfaces. Heparin 38-45 coagulation factor III, tissue factor Homo sapiens 113-126 20431847-1 2010 Antithrombin (AT), in the presence of heparin, is able to inhibit the catalytic activity of factor VIIa bound to tissue factor (TF) on cell surfaces. Heparin 38-45 coagulation factor III, tissue factor Homo sapiens 128-130 20434010-8 2010 As heparins are strong inhibitor of heparanase, in view of the effect of heparanase on TF, the role of heparins anticoagulant-activity may potentially be expanded. Heparin 3-11 coagulation factor III, tissue factor Homo sapiens 87-89 19377079-0 2009 Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins. Heparin 119-127 coagulation factor III, tissue factor Homo sapiens 0-13 19377079-11 2009 Finally, the profibrinolytic effect of unfractionated heparin and enoxaparin was markedly lower (approximately 50%) in the presence of LPS-MNC than in the presence of a thromboplastin preparation displaying an identical tissue factor activity. Heparin 54-61 coagulation factor III, tissue factor Homo sapiens 220-233 19377079-12 2009 CONCLUSIONS: Our data indicate that LPS-stimulated monocytes inhibit fibrinolysis through a tissue factor-mediated enhancement of thrombin activatable fibrinolysis inhibitor activation and make clots resistant to the profibrinolytic activity of heparins, thus providing an additional mechanism whereby tissue factor-expressing monocytes/macrophages may favor fibrin accumulation and diminish the antithrombotic efficacy of heparins. Heparin 245-253 coagulation factor III, tissue factor Homo sapiens 92-105 19377079-12 2009 CONCLUSIONS: Our data indicate that LPS-stimulated monocytes inhibit fibrinolysis through a tissue factor-mediated enhancement of thrombin activatable fibrinolysis inhibitor activation and make clots resistant to the profibrinolytic activity of heparins, thus providing an additional mechanism whereby tissue factor-expressing monocytes/macrophages may favor fibrin accumulation and diminish the antithrombotic efficacy of heparins. Heparin 423-431 coagulation factor III, tissue factor Homo sapiens 92-105 12586136-0 2002 Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin. Heparin 156-163 coagulation factor III, tissue factor Homo sapiens 0-13 17167048-6 2007 In comparison, UFH or ATH heparin binding (evidence of a template mechanism) was only observed with thrombin, tissue factor, FIXa and FXIa. Heparin 15-18 coagulation factor III, tissue factor Homo sapiens 110-123 17167048-6 2007 In comparison, UFH or ATH heparin binding (evidence of a template mechanism) was only observed with thrombin, tissue factor, FIXa and FXIa. Heparin 26-33 coagulation factor III, tissue factor Homo sapiens 110-123 16376423-7 2006 These studies are the first to demonstrate the additive effect of surface bound heparin and TM as a combined interactive strategy to limit TF-induced thrombin formation. Heparin 80-87 coagulation factor III, tissue factor Homo sapiens 139-141 15718352-0 2005 Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma. Heparin 25-32 coagulation factor III, tissue factor Homo sapiens 92-105 15718352-5 2005 After strong activation with high amounts of TF (30 microM), the thrombin potential was significantly more suppressed in cord plasma compared with adult plasma in the presence of 0.4 IE/mL heparin (-92 versus -75%; p < 0.01) and in the presence of 2 IE/mL hirudin (-18 versus -8%; p < 0.01). Heparin 189-196 coagulation factor III, tissue factor Homo sapiens 45-47 15718352-6 2005 In contrast, after weak activation with low amounts of TF (30 pM), the thrombin potential was significantly more suppressed in adult plasma compared with neonatal plasma in the presence of 0.025 IE/mL heparin (-93 versus -8%; p < 0.01) and in the presence of 2 IE/mL hirudin (-89 versus -48%; p < 0.01). Heparin 201-208 coagulation factor III, tissue factor Homo sapiens 55-57 15034796-8 2004 Anticoagulants, such as low-molecular-weight heparin, may act to prevent these complications both by interfering with TF-mediated activation of clotting and by directly down-regulating angiogenesis. Heparin 45-52 coagulation factor III, tissue factor Homo sapiens 118-120 14686601-13 2003 Heparin inhibited TF by >90%, but prolonged TEG-r by 97.4+/-1.6 min (1 U ml(-1)); FEPP inhibited TF by >90% (100 microg ml(-1)) and prolonged TEG-r by 73.7+/-8.4 min (10 microg ml(-1)). Heparin 0-7 coagulation factor III, tissue factor Homo sapiens 18-20 14686601-13 2003 Heparin inhibited TF by >90%, but prolonged TEG-r by 97.4+/-1.6 min (1 U ml(-1)); FEPP inhibited TF by >90% (100 microg ml(-1)) and prolonged TEG-r by 73.7+/-8.4 min (10 microg ml(-1)). Heparin 0-7 coagulation factor III, tissue factor Homo sapiens 100-102 12808176-1 2003 BACKGROUND: Heparin inhibits prothrombotic tissue factor (TF) and releases its inhibitor, tissue factor pathway inhibitor (TFPI), from the endothelium, but repeated administration of heparin depletes vascular stores of TFPI. Heparin 12-19 coagulation factor III, tissue factor Homo sapiens 43-56 12808176-1 2003 BACKGROUND: Heparin inhibits prothrombotic tissue factor (TF) and releases its inhibitor, tissue factor pathway inhibitor (TFPI), from the endothelium, but repeated administration of heparin depletes vascular stores of TFPI. Heparin 12-19 coagulation factor III, tissue factor Homo sapiens 58-60 12808176-8 2003 In patients switched to UFH, TF levels remained unchanged compared with pre-randomization values, TFPI increased at each interval of HD sessions (all P<0.035) and PF 1+2 increased pre-dialysis (P=0.015). Heparin 24-27 coagulation factor III, tissue factor Homo sapiens 29-31 12626202-0 2002 Cell adhesion and tissue factor upregulation in oxygenators used during coronary artery bypass grafting are modified by the Corline Heparin Surface. Heparin 132-139 coagulation factor III, tissue factor Homo sapiens 18-31 12626202-8 2002 The coated group with high level of heparin showed higher surface-expression of TF with low levels of TFmRNA. Heparin 36-43 coagulation factor III, tissue factor Homo sapiens 80-82 12626202-9 2002 CONCLUSION: The CHS was most biocompatible with the standard level of heparin used during CABG whereas elevation of systemic heparin rather increased the activation and TF upregulation in monocytes from oxygenators. Heparin 125-132 coagulation factor III, tissue factor Homo sapiens 169-171 18645924-10 2008 As heparins are strong inhibitors of heparanase, in view of the effect of heparanase on TF/TFPI pathway, the role of heparins" anticoagulant activity may potentially be expanded. Heparin 3-11 coagulation factor III, tissue factor Homo sapiens 88-90 12801846-8 2003 With long periods of incubation (24-48h), both unfractionated heparin and enoxaparin significantly increased TFPI release (control vs. unfractionated heparin, p<0.05-0.001; control vs. enoxaparin, p<0.01-0.001) and also reduced the release of vWF in the culture medium, though no variations in endothelial cell procoagulant activity or TF content were observed. Heparin 62-69 coagulation factor III, tissue factor Homo sapiens 109-111 11493478-0 2001 Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Heparin 30-37 coagulation factor III, tissue factor Homo sapiens 100-113 12028043-0 2002 Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term low-molecular-weight heparin administration. Heparin 124-131 coagulation factor III, tissue factor Homo sapiens 0-13 12028043-8 2002 This study provides evidence that low-molecular-weight heparin (LMWH) administration, in addition to a reduction of hypercoagulability and a mild fibrinolytic activation, is associated with decreased TF levels, so indicating a novel mechanism of interference of LMWH with the haemostatic system. Heparin 55-62 coagulation factor III, tissue factor Homo sapiens 200-202 11991242-9 2002 Both doses of UFH, but not Bemiparin, induced an important increase in TF secretion. Heparin 14-17 coagulation factor III, tissue factor Homo sapiens 71-73 11772296-9 2001 TFPI can be administered exogenously in high doses to suppress TF-mediated effects, alternatively high amounts of TFPI can be released from intravascular stores by other drugs, such as heparin and low molecular weight heparins (LMWH). Heparin 218-226 coagulation factor III, tissue factor Homo sapiens 0-2 11254842-11 2001 CONCLUSION: These data indicate that TFPI release by heparin probably has an important role in the suppression of the tissue factor-dependent coagulation pathway during CPB. Heparin 53-60 coagulation factor III, tissue factor Homo sapiens 118-131 11342462-0 2001 Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Heparin 64-71 coagulation factor III, tissue factor Homo sapiens 22-35 10604885-6 1999 UFH and LMWH markedly decreased activation of coagulation caused by LPS, as F(1+2) and TpP levels only slightly increased; TF expression on monocytes was also markedly reduced by UFH. Heparin 0-3 coagulation factor III, tissue factor Homo sapiens 123-125 10828477-10 2000 After heparin the patients released higher amounts of tissue factor pathway inhibitor antigen and activity compared with the control group; however, the difference was not statistically significant. Heparin 6-13 coagulation factor III, tissue factor Homo sapiens 54-67 10604885-6 1999 UFH and LMWH markedly decreased activation of coagulation caused by LPS, as F(1+2) and TpP levels only slightly increased; TF expression on monocytes was also markedly reduced by UFH. Heparin 179-182 coagulation factor III, tissue factor Homo sapiens 123-125 10604885-7 1999 TF pathway inhibitor values increased after either heparin infusion (P<0.01). Heparin 51-58 coagulation factor III, tissue factor Homo sapiens 0-2 10844403-9 1999 Our results show that unfractionated and low molecular weight heparins potently inhibit monocytic tissue factor induced thrombin generation. Heparin 62-70 coagulation factor III, tissue factor Homo sapiens 98-111 10348708-0 1999 Effects of heparin and related sulfated polysaccharides on tissue factor expression induced by mitogenic and non-mitogenic factors in human vascular smooth muscle cells. Heparin 11-18 coagulation factor III, tissue factor Homo sapiens 59-72 10545520-5 1999 Immobilized heparin, a mimic for extracellular matrix-associated proteoglycans, binds physiological concentrations of TFPI-1 in a conformation that supports TF-VIIa-dependent cell adhesion. Heparin 12-19 coagulation factor III, tissue factor Homo sapiens 118-120 10235445-2 1999 In in vitro experiments heparin is able to blunt monocyte TF production by inhibiting TF and cytokine gene expression by stimulated cells and after in vivo administration it reduces adverse ischemic outcomes in UA patients. Heparin 24-31 coagulation factor III, tissue factor Homo sapiens 58-60 10235445-2 1999 In in vitro experiments heparin is able to blunt monocyte TF production by inhibiting TF and cytokine gene expression by stimulated cells and after in vivo administration it reduces adverse ischemic outcomes in UA patients. Heparin 24-31 coagulation factor III, tissue factor Homo sapiens 86-88 10235445-5 1999 Four h after the heparin injection TF furtherly decreased (176.5 pg/ml, 87.5-321 pg/ml; -32.5%. Heparin 17-24 coagulation factor III, tissue factor Homo sapiens 35-37 10235445-9 1999 In conclusion, heparin treatment is associated with a decrease of high TF plasma levels and monocyte procoagulant activity in UA patients. Heparin 15-22 coagulation factor III, tissue factor Homo sapiens 71-73 10697424-9 1999 High activity of the tissue factor and substances neutralizing heparin may intensify the thrombus growth. Heparin 63-70 coagulation factor III, tissue factor Homo sapiens 21-34 10348708-9 1999 TF expression induced by the growth factors was inhibited by heparin (IC 50: 10-30 microg/ml), and other sulfated polysaccharides (IC 50: 1-5 microg/ml). Heparin 61-68 coagulation factor III, tissue factor Homo sapiens 0-2 10348708-12 1999 These results indicate that, besides its well known effect on SMC proliferation, heparin displays an inhibitory effect on cell mediated blood clotting processes through regulation of the TF expression. Heparin 81-88 coagulation factor III, tissue factor Homo sapiens 187-189 10348708-5 1999 We evaluated the inhibitory effect of heparin on the expression of TF induced by various mitogenic (FCS, PDGF-BB and EGF) and non-mitogenic (bacterial LPS) agents. Heparin 38-45 coagulation factor III, tissue factor Homo sapiens 67-69 9459343-13 1998 Unfractionated heparin infused through a mixing device proximal to the perfusion chamber to obtain plasma concentrations of 0.5, 1 and 3 IU/ml, reduced fibrin deposition on TF-coated coverslips in a dose-dependent manner (77% reduction at 3 IU/ml, p <0.01), but had no significant effect on platelet deposition (33% at 3 IU/ml, p >0.05). Heparin 15-22 coagulation factor III, tissue factor Homo sapiens 173-175 9674734-1 1998 Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of tissue factor (TF)-induced blood coagulation, which is increased several-fold in post-heparin plasma and thought to contribute significantly to the antithrombotic action of heparin. Heparin 237-244 coagulation factor III, tissue factor Homo sapiens 33-35 9674734-0 1998 Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Heparin 38-45 coagulation factor III, tissue factor Homo sapiens 96-109 9674734-0 1998 Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Heparin 71-78 coagulation factor III, tissue factor Homo sapiens 96-109 9674734-1 1998 Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of tissue factor (TF)-induced blood coagulation, which is increased several-fold in post-heparin plasma and thought to contribute significantly to the antithrombotic action of heparin. Heparin 150-157 coagulation factor III, tissue factor Homo sapiens 64-77 9674734-1 1998 Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of tissue factor (TF)-induced blood coagulation, which is increased several-fold in post-heparin plasma and thought to contribute significantly to the antithrombotic action of heparin. Heparin 150-157 coagulation factor III, tissue factor Homo sapiens 33-35 9674734-1 1998 Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of tissue factor (TF)-induced blood coagulation, which is increased several-fold in post-heparin plasma and thought to contribute significantly to the antithrombotic action of heparin. Heparin 237-244 coagulation factor III, tissue factor Homo sapiens 64-77 9157959-4 1997 An earlier study showed that growing primary cultures of human umbilical vein endothelial cells (HUVECs) with endothelial cell growth supplement (ECGS) and heparin had impaired the ability of monolayers to express surface membrane TF activity after perturbation. Heparin 156-163 coagulation factor III, tissue factor Homo sapiens 231-233 9058497-5 1997 In the presence of heparin, AT was bound to the FVIIa/TF complex in a dose-dependent manner with ka of 2 x 10(3) M-1 s-1. Heparin 19-26 coagulation factor III, tissue factor Homo sapiens 54-56 8790153-0 1996 Induction of monocyte tissue factor procoagulant activity during coronary artery bypass surgery is reduced with heparin-coated extracorporeal circuit. Heparin 112-119 coagulation factor III, tissue factor Homo sapiens 22-35 9200337-0 1997 Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin. Heparin 114-121 coagulation factor III, tissue factor Homo sapiens 0-13 8950777-3 1996 The present study was conducted to investigate how repeated (n = 8) and continuous (n = 6) administration of heparin affect plasma TFPI and the inhibition of tissue factor (TF)-induced coagulation ex vivo in humans. Heparin 109-116 coagulation factor III, tissue factor Homo sapiens 158-171 8950777-3 1996 The present study was conducted to investigate how repeated (n = 8) and continuous (n = 6) administration of heparin affect plasma TFPI and the inhibition of tissue factor (TF)-induced coagulation ex vivo in humans. Heparin 109-116 coagulation factor III, tissue factor Homo sapiens 131-133 8950777-8 1996 The contribution of TFPI to the inhibition of TF-induced coagulation during heparin infusion was estimated to decrease from 60 +/- 15% to 20 +/- 10% (p < 0.0001). Heparin 76-83 coagulation factor III, tissue factor Homo sapiens 20-22 7803789-4 1995 AT III alone and AT III/heparin to a greater extent reduced factor VIIa bound to cell surface TF. Heparin 24-31 coagulation factor III, tissue factor Homo sapiens 94-96